<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884243</url>
  </required_header>
  <id_info>
    <org_study_id>CBT-CS102</org_study_id>
    <nct_id>NCT04884243</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction</brief_title>
  <official_title>A Phase 2 Multicenter, Double-masked, Randomized, Vehicle-controlled, Parallel Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cloudbreak Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cloudbreak Therapeutics, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      STUDY DESIGN&#xD;
&#xD;
      Structure:&#xD;
&#xD;
      Multicenter, randomized, double-masked, vehicle-controlled, parallel group study.&#xD;
&#xD;
      Duration:&#xD;
&#xD;
      3 months of TID treatment.&#xD;
&#xD;
      Treatment Groups, Dosing, and Treatment Regimen:&#xD;
&#xD;
      Study Treatment: CBT-006 topical ophthalmic solution Control Treatment: CBT-006 vehicle&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 5, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Visual acuity, biomicroscopy, intraocular pressure, ophthalmoscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular discomfort score (0-4)</measure>
    <time_frame>3 months</time_frame>
    <description>Change of the ocular discomfort score from baseline (Day 1) at Week 12; Score 0 is the most comfortable and 4 is the least comfortable</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>CBT-006</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2.5% CBT-006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10% CBT-006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBT-006</intervention_name>
    <description>Cyclodextrin</description>
    <arm_group_label>10% CBT-006</arm_group_label>
    <arm_group_label>2.5% CBT-006</arm_group_label>
    <arm_group_label>CBT-006</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with MGD in both eyes and meet the following:&#xD;
&#xD;
               1. Ocular discomfort Score (ODS) ≥ 2 (No discomfort = 0, slight discomfort = 1, mild&#xD;
                  discomfort = 2, moderate discomfort = 3, severe discomfort = 4)&#xD;
&#xD;
               2. Visual Analog Scale (VAS) level is 35-90% for at least 1 of the 7 categories&#xD;
&#xD;
               3. Total Cornea staining grade ≥ 3 (NEI scheme with max score = 15)&#xD;
&#xD;
               4. Total meibum quality score (MQS) is between 6-17 from the sum of the 6 lower&#xD;
                  eyelid central glands in at least one lower eyelid (0-3 scale with max total =&#xD;
                  18).&#xD;
&#xD;
               5. TBUT ≤ 5 s&#xD;
&#xD;
               6. Schirmer I Test (anaesthetized) ≥ 5 mm/5 min in study eye&#xD;
&#xD;
               7. BCVA LogMAR ≥ +0.7 in each eye&#xD;
&#xD;
          -  All patients of both genders ≥ 18 years&#xD;
&#xD;
          -  Willing to withhold the use of artificial tears and lubricants during the treatment&#xD;
             phase;&#xD;
&#xD;
          -  Able to provide written informed consent and comply with study assessments for the&#xD;
             full duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled systemic disease in the opinion of the Investigator&#xD;
&#xD;
          -  Active allergies with symptoms that may confound the data, active ocular infection&#xD;
             requiring treatment, or ocular surface inflammatory disease unrelated to MGD or DED,&#xD;
             including chalazion, inflamed pinguecula, and viral illness&#xD;
&#xD;
          -  History of ocular herpes disease in either eye&#xD;
&#xD;
          -  Incisional ocular surgery within 6 months or ocular laser surgery within 3 months&#xD;
&#xD;
          -  Use of topical treatment of the eye/eyelid with antibiotics, NSAIDS, or&#xD;
             vasoconstrictors to treat MGD or DED within 14 days of screening; steroids,&#xD;
             cyclosporin A or lifitegrast within 28 days of screening&#xD;
&#xD;
          -  Current or anticipated use of other topical ophthalmic medications in the study eye.&#xD;
             (Patients must have discontinued the use of ophthalmic medications in the study eye&#xD;
             for at least 2 weeks prior to the screening visit, the use of diagnostic medications&#xD;
             as part of the eye exam prior to screening and artificial tears is allowed.)&#xD;
&#xD;
          -  Anticipated wearing of contact lenses during any portion of the study. (Patients, who&#xD;
             wear soft contact lenses should discontinue wearing them at least 3 days prior to&#xD;
             screening visit. Patients wearing rigid gas permeable or hard contact lenses should&#xD;
             discontinue wearing them at least 3 weeks prior to screening visit.)&#xD;
&#xD;
          -  Active rosacea involving the eyelids within 60 days of screening&#xD;
&#xD;
          -  Current enrollment in an investigational drug or device study or participation in such&#xD;
             a study within 30 days prior to entry into this study&#xD;
&#xD;
          -  Any condition or situation which, in the investigator's opinion, may put the patient&#xD;
             at significant risk, may confound the study results, or may interfere significantly&#xD;
             with the patient's participation in the study&#xD;
&#xD;
          -  Female patients who are pregnant, nursing, or planning a pregnancy during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bing Leng</last_name>
    <phone>9493952891</phone>
    <email>leng_bing@cloudbreaktherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Van Dinh</last_name>
    <phone>9493945308</phone>
    <email>dinh_van@cloudbreaktherapeutics.com</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meibomian Gland Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

